OBJECTIVE: To explore the incidence of various types of mucopolysaccharidosis (MPS) and their clinical characteristics. METHODS: A total of 75 children highly suspected as having MPS underwent quantitative and electrophoretic analysis of urinary glycosaminoglycans (GAGs) and enzymatic analysis of seven types of MPS from January 2009 to December 2011. Fluorescence assay was used to measure the activities of α-L-iduronidase, iduronate-2-sulfatase, α-N-acetylglucosaminidase, galactosamine-6-sulfatase, β-galactosidase, arylsulfatase B and β-glucuronidase in the white blood cells. RESULTS: A total of 52 cases were confirmed with MPS based on clinical, radiological, and enzymatic examinations. The 52 cases, with a mean age of 4.0±2.2 years, included 5 cases of MPS I (10%), 20 cases of MPS II (38%), 20 cases of MPS IVA (38%), 6 cases of MPS VI (12%) and 1 case of MPS VII (2%). No MPS IV B cases or MPS IIIB cases were found. Compared with healthy children of the same age, the GAG/Cr ratio was significantly elevated in 50 confirmed cases of MPS (two MPS IVA cases having no increased ratio). All children with increased urinary GAGs had a confirmed diagnosis of MPS. The age of onset was between 1 and 2 years after birth in most cases, and often complicated by hernia and valvular heart disease. Children with MPS I, MPS II, and MPS VI presented with ugly and unsmooth face, short stature, joint stiffness, and limitation of motion, while children with MPS IVA presented with short stature, skeletal dysplasia, and joint laxity. CONCLUSIONS: Type IVA and type II are the most common in MPS cases, followed by type VI and type I. MPS children are characterized by special appearances including ugly and unsmooth facial appearance, short stature and skeletal dysplasia. Quantitative analysis of urinary GAG, as a simple, rapid, and reliable method, is recommended for screening of MPS.
Key words
Mucopolysaccharidosis /
Enzymatic assay /
Urinary glycosaminoglycans /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］赵小媛，黄永兰，社勇，林文春，周志红，刘丽. 尿黏多糖定量测定及其临床应用［J］.中国儿童保健杂志，2010，18（11）：885-888.
［2］林群娣，光炜，蒋玮莹. 琼脂糖凝胶电泳检测尿黏多糖方法的建立［J］. 广东医学，1999，20（9）：694.
［3］张惠文，王瑜，叶军，邱文娟，韩连书，高晓岚，等. 黏多糖贮积症47例的常见酶学分型［J］. 中华儿科杂志，2009，47（4）：276-280.
［4］Beesley CE, Meaney CA, Greenland G, Adams V, Vellodi A, Young EP, et al. Mutational analysis of 85 mucopelysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations［J］. Hum Genet, 2001, 109(5): 503-511.
［5］Voznyi YV, Keulemans JL, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease) ［J］. J Inherit Metab Dis, 2001, 24(6): 675-680.
［6］Kleijer WJ, Geilen GC, Garritsen V, Huijmans JG, Los FJ, Voznyi YV, et al. First-trimester diagnosis of Morquio disease type A［J］. Prenat Diagn, 2000, 20(3): 183-185.
［7］Iwasaki H, Watanabe H, Iida M, Ogawa S, Tabe M, Higaki K, et al. Fibroblast screening for chaperone therapy in beta-galactnsidosis［J］. Brain Dev, 2006, 28(8): 482-486.
［8］Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: Enzymatic diagnosis in dried blood spots on filter paper［J］. Clin Chem, 2001, 47(12): 2098-2102.
［9］郭玉风，施惠平，张为民，罗会元，韩璐亚，赵时敏．黏多糖贮积症Ⅵ型的病例诊断与产前诊断［J］. 中国优生遗传杂志，1995，3（2）：21-24.
［10］Vervoort R, Gitzelmann R, Bosshard N, Maire I, Liebaers I, Lissens W. Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote［J］. Hum Genet, 1998, 102(1):69-78.
［11］Marsh J, Fensom AH. 4-Methylumbelliferyl alpha-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease［J］. Clin Genet, 1985, 27(3): 258-262.
［12］Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004［J］. Am J Med Genet A, 2009, 149A(5): 960-964.
［13］Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany［J］. J Inherit Metab Dis, 2005, 28(6): 1011-1017.
［14］Coelho JC, Wajner M, Burin MG, Vargas CR, Giugliani R. Selective screening of 10000 high-risk Brazilian patients for the detection of inborn errors of metabolism［J］. Eur J Pediatr, 1997, 156(8): 650-654.
［15］Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia［J］. Am J Med Genet A, 2003, 123A(3): 310-313.
［16］Alonso-Fernández JR, Fidalgo J, Colón C. Neonatal screening for mucopolysaccharidoses by determination of glycosaminoglycans in the eluate of urine-impregnated paper: preliminary results of an improved DMB-based procedure［J］. J Clin Lab Anal, 2010, 24(3): 149-153.
［17］da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome) ［J］. Cochrane Database Syst Rev, 2011, (11): CD008185.
［18］黄永兰，李社勇，赵小媛，刘鸿圣，区小冰，刘丽. 黏多糖病Ⅶ型一例并文献复习［J］. 中华儿科杂志, 2011, 49(6): 455-458.
［19］Monta-o AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry:clinical manifestation and natural course of Morquio A disease［J］. J Inherit Metab Dis, 2007, 30(2): 165-174.
［20］Nelson J, Thomas PS. Clinical findings in 12 patients with MPS IV A (Morquio′s disease). Further evidence for heterogeneity. Part III: Odontoid dysplasia［J］. Clin Genet, 1988, 33(2): 126-130.
［21］Ransford AO, Crockard HA, Stevens JM, Modaghegh S. Occipito-atlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience［J］. J Bone Joint Surg Br, 1996, 78(2): 307-313.
［22］John A, Fagondes S, Schwartz I, Azevedo AC, Barrios P, Dalcin P, et al. Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI［J］. Am J Med Genet A, 2011, 155A(7): 1546-1551.
［23］Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, et al. A clinical study of 77 patients with mucopolysaccharidosis type II［J］. Acta Paediatr Suppl, 2007, 96(455):63-70.
［24］Sohn YB, Choi EW, Kim SJ, Park SW, Kim SH, Cho SY, et al. Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: Emphasis on the cardiovascular complication and mortality cases［J］. Am J Med Genet A, 2011, doi: 10.1002/ajmg.a.34371［Epub ahead of print］.
［25］Scarpa M, Almássy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease［J］. Orphanet J Rare Dis, 2011, 6: 72.
PDF(1017 KB)
